Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Oscar Health Inc (NYSE: OSCR) closed the day trading at $18.77 down -8.62% from the previous closing price of $20.54. In other words, the price has decreased by -$8.62 from its previous closing price. On the day, 25.44 million shares were traded. OSCR stock price reached its highest trading level at $21.185 during the session, while it also had its lowest trading level at $18.665.
Ratios:
For a better understanding of OSCR, let’s look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
On July 15, 2025, UBS Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $11.
Piper Sandler Downgraded its Overweight to Neutral on July 14, 2025, while the target price for the stock was maintained at $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 22 ’25 when Schlosser Mario sold 395,000 shares for $18.43 per share. The transaction valued at 7,279,850 led to the insider holds 501,148 shares of the business.
MARIO T SCHLOSSER bought 395,000 shares of OSCR for $7,280,996 on Sep 22 ’25. On Jun 20 ’25, another insider, RANMALI BOPITIYA, who serves as the Officer of the company, bought 30,000 shares for $18.77 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OSCR now has a Market Capitalization of 4853137920 and an Enterprise Value of 1670339072. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.45 while its Price-to-Book (P/B) ratio in mrq is 4.19. Its current Enterprise Value per Revenue stands at 0.156 whereas that against EBITDA is -16.867.
Stock Price History:
The Beta on a monthly basis for OSCR is 1.88, which has changed by 0.06769061 over the last 52 weeks, in comparison to a change of 0.118204355 over the same period for the S&P500. Over the past 52 weeks, OSCR has reached a high of $23.80, while it has fallen to a 52-week low of $11.20. The 50-Day Moving Average of the stock is 5.98%, while the 200-Day Moving Average is calculated to be 20.52%.
Shares Statistics:
Over the past 3-months, OSCR traded about 23.70M shares per day on average, while over the past 10 days, OSCR traded about 21437420 shares per day. A total of 222.91M shares are outstanding, with a floating share count of 189.35M. Insiders hold about 26.77% of the company’s shares, while institutions hold 55.81% stake in the company. Shares short for OSCR as of 1759190400 were 41969509 with a Short Ratio of 1.77, compared to 1756425600 on 49623860. Therefore, it implies a Short% of Shares Outstanding of 41969509 and a Short% of Float of 20.919999999999998.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of Oscar Health Inc (OSCR) in the stock market.The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.84 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$1.08 and -$1.91 for the fiscal current year, implying an average EPS of -$1.39. EPS for the following year is -$0.32, with 7.0 analysts recommending between $0.16 and -$1.06.
Revenue Estimates
7 analysts predict $3.09B in revenue for. The current quarter. It ranges from a high estimate of $3.13B to a low estimate of $3.05B. As of. The current estimate, Oscar Health Inc’s year-ago sales were $2.42BFor the next quarter, 7 analysts are estimating revenue of $3.06B. There is a high estimate of $3.09B for the next quarter, whereas the lowest estimate is $3.03B.
A total of 7 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $12.11B, while the lowest revenue estimate was $11.99B, resulting in an average revenue estimate of $12.06B. In the same quarter a year ago, actual revenue was $9.18BBased on 7 analysts’ estimates, the company’s revenue will be $11.31B in the next fiscal year. The high estimate is $12.13B and the low estimate is $10.9B.
